A randomised, double‐blind, trial of the safety and efficacy of omarigliptin (a once‐weekly DPP‐4 inhibitor) in subjects with type 2 diabetes and renal impairment
Antonio Chacra; Ira Gantz; Geraldine Mendizabal; Lucila Durlach; Edward A. O'Neill; Zachary Zimmer; Shailaja Suryawanshi; Samuel S. Engel; Eseng Lai
Author Information: Diabetes Center
|Checking for direct PDF access through Ovid|
Abstract unavailable for this article.